S. Sugarman

579 total citations
16 papers, 410 citations indexed

About

S. Sugarman is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, S. Sugarman has authored 16 papers receiving a total of 410 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Cancer Research and 3 papers in Molecular Biology. Recurrent topics in S. Sugarman's work include Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (5 papers) and Neutropenia and Cancer Infections (3 papers). S. Sugarman is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (5 papers) and Neutropenia and Cancer Infections (3 papers). S. Sugarman collaborates with scholars based in United States and Singapore. S. Sugarman's co-authors include Richard Pazdur, Yehuda Z. Patt, Jaffer A. Ajani, Yvonne Lassere, James L. Abbruzzese, Verna A. Rhodes, Avi B. Markowitz, C. Hudis, Shanu Modi and Alison L. Hannah and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

S. Sugarman

16 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Sugarman United States	9	332	101	100	61	50	16	410
Corrado Gallo Stampino Italy	12	238 0.7×	183 1.8×	103 1.0×	33 0.5×	58 1.2×	31	419
Giuseppe Colantuoni Italy	13	317 1.0×	185 1.8×	182 1.8×	42 0.7×	86 1.7×	28	509
Karel Cwiertka Czechia	10	247 0.7×	115 1.1×	123 1.2×	48 0.8×	108 2.2×	45	436
Maria Alessandra Calegari Italy	10	220 0.7×	89 0.9×	109 1.1×	56 0.9×	70 1.4×	43	361
I. Mandjes Netherlands	4	294 0.9×	94 0.9×	48 0.5×	50 0.8×	32 0.6×	4	408
Jara M. Baas Netherlands	11	221 0.7×	81 0.8×	87 0.9×	71 1.2×	114 2.3×	15	339
Nebojša Manojlović Serbia	8	215 0.6×	58 0.6×	49 0.5×	46 0.8×	54 1.1×	25	277
Serena Ricciardi Italy	11	342 1.0×	178 1.8×	287 2.9×	49 0.8×	59 1.2×	27	545
Luis Manuel Martínez-Barrera Mexico	10	271 0.8×	158 1.6×	270 2.7×	30 0.5×	72 1.4×	23	524
WC Wood United States	4	226 0.7×	41 0.4×	136 1.4×	39 0.6×	129 2.6×	5	334

Countries citing papers authored by S. Sugarman

Since Specialization

Citations

This map shows the geographic impact of S. Sugarman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Sugarman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Sugarman more than expected).

Fields of papers citing papers by S. Sugarman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Sugarman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Sugarman. The network helps show where S. Sugarman may publish in the future.

Co-authorship network of co-authors of S. Sugarman

This figure shows the co-authorship network connecting the top 25 collaborators of S. Sugarman. A scholar is included among the top collaborators of S. Sugarman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Sugarman. S. Sugarman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Smyth, Lillian M., Neil M. Iyengar, Sujata Patil, et al.. (2016). Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Research and Treatment. 158(1). 91–97. 20 indexed citations

Jhaveri, Komal, Sarat Chandarlapaty, Diana Lake, et al.. (2011). P1-17-08: A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC).. Cancer Research. 71(24_Supplement). P1–17. 7 indexed citations

Rugo, H. S., et al.. (2009). Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: no evidence of short-term changes in left ventricular ejection fraction.. Cancer Research. 69(2_Supplement). 4102–4102. 2 indexed citations

Rugo, Hope, Qiuping Zhou, Mark M. Moasser, et al.. (2009). Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer.. Cancer Research. 69(2_Supplement). 4104–4104. 11 indexed citations

Drullinsky, Pamela, Monica Fornier, S. Sugarman, et al.. (2009). Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10–11-day dosing intervals for women with early-stage breast cancer. Journal of Clinical Oncology. 27(15_suppl). 590–590. 2 indexed citations

Modi, Shanu, S. Sugarman, A. Stopeck, et al.. (2008). Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1027–1027. 50 indexed citations

Seidman, A. D., Alison Conlin, Mary Ellen Moynahan, et al.. (2008). Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: an interim safety analysis. European Journal of Cancer Supplements. 6(7). 219–219. 1 indexed citations

Dickler, Maura N., K. Panageas, Richard M. Steingart, et al.. (2007). Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin- bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety. Journal of Clinical Oncology. 25(18_suppl). 567–567. 5 indexed citations

Smith, Charmaine, S. Sugarman, Tiffany A. Troso-Sandoval, et al.. (2006). Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA). Journal of Clinical Oncology. 24(18_suppl). 582–582. 13 indexed citations

10.

Madajewicz, Stefan, Rafael C. Caruso, Michael Fried, et al.. (2000). Phase I Chemotherapy Study of Biochemical Modulation of Folinic Acid and Fluorouracil by Gemcitabine in Patients With Solid Tumor Malignancies. Journal of Clinical Oncology. 18(20). 3553–3557. 32 indexed citations

11.

Sugarman, S., et al.. (1996). Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Cancer Chemotherapy and Pharmacology. 37(6). 531–538. 33 indexed citations

12.

Abbruzzese, James L., Timothy Madden, S. Sugarman, et al.. (1996). Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.. PubMed. 2(9). 1489–97. 16 indexed citations

13.

Pazdur, Richard, J. L. Abbruzzese, Avi B. Markowitz, et al.. (1995). Phase II Trial of Isotretinoin and Recombinant Interferon Alfa-2a in Metastatic Colorectal Carcinoma. American Journal of Clinical Oncology. 18(5). 436–438. 2 indexed citations

14.

Pazdur, Richard, Yvonne Lassere, Jaffer A. Ajani, et al.. (1994). Phase II trial of docetaxel (Taxotere®) in metastatic colorectal carcinoma. Annals of Oncology. 5(5). 468–470. 44 indexed citations

15.

Pazdur, Richard, Yvonne Lassere, Verna A. Rhodes, et al.. (1994). Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.. Journal of Clinical Oncology. 12(11). 2296–2300. 170 indexed citations

16.

Loggie, Jennifer M.H., Philip J. Privitera, S. Sugarman, & T E Gaffney. (1968). Effects of Hydrocortisone on Survival in Neonatal Beagles Given Endotoxin. Experimental Biology and Medicine. 128(1). 326–329. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact